HRP20230696T1 - Liječenje hereditarnog angioedema - Google Patents
Liječenje hereditarnog angioedema Download PDFInfo
- Publication number
- HRP20230696T1 HRP20230696T1 HRP20230696TT HRP20230696T HRP20230696T1 HR P20230696 T1 HRP20230696 T1 HR P20230696T1 HR P20230696T T HRP20230696T T HR P20230696TT HR P20230696 T HRP20230696 T HR P20230696T HR P20230696 T1 HRP20230696 T1 HR P20230696T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- solvate
- pharmaceutically acceptable
- formula
- acceptable salt
- Prior art date
Links
- 206010019860 Hereditary angioedema Diseases 0.000 title claims 18
- 238000011282 treatment Methods 0.000 title claims 5
- 150000001875 compounds Chemical class 0.000 claims 53
- 150000003839 salts Chemical class 0.000 claims 51
- 239000012453 solvate Substances 0.000 claims 51
- 230000001154 acute effect Effects 0.000 claims 14
- 208000024891 symptom Diseases 0.000 claims 6
- 206010042674 Swelling Diseases 0.000 claims 3
- 230000008961 swelling Effects 0.000 claims 3
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 2
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 2
- 230000003466 anti-cipated effect Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000006186 oral dosage form Substances 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 230000001960 triggered effect Effects 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010013952 Dysphonia Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010015216 Erythema marginatum Diseases 0.000 claims 1
- 108010080865 Factor XII Proteins 0.000 claims 1
- 102000000429 Factor XII Human genes 0.000 claims 1
- 108010071241 Factor XIIa Proteins 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000010473 Hoarseness Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 206010027951 Mood swings Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000037048 Prodromal Symptoms Diseases 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 230000002250 progressing effect Effects 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 230000009747 swallowing Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000004916 vomit Anatomy 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861725P | 2019-06-14 | 2019-06-14 | |
| GBGB1910116.1A GB201910116D0 (en) | 2019-07-15 | 2019-07-15 | Treatments of hereditary angioedema |
| PCT/GB2020/051439 WO2020249977A1 (en) | 2019-06-14 | 2020-06-15 | Treatments of hereditary angioedema |
| EP20734283.3A EP3982960B1 (en) | 2019-06-14 | 2020-06-15 | Treatments of hereditary angioedema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230696T1 true HRP20230696T1 (hr) | 2023-10-13 |
Family
ID=67700145
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230696TT HRP20230696T1 (hr) | 2019-06-14 | 2020-06-15 | Liječenje hereditarnog angioedema |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20220218680A1 (https=) |
| EP (2) | EP4282474A3 (https=) |
| JP (3) | JP7356518B2 (https=) |
| KR (1) | KR102748728B1 (https=) |
| CN (1) | CN114126612A (https=) |
| AR (1) | AR119158A1 (https=) |
| AU (1) | AU2020293614B2 (https=) |
| BR (1) | BR112021024664A2 (https=) |
| CA (1) | CA3142218A1 (https=) |
| CL (2) | CL2021003244A1 (https=) |
| DK (1) | DK3982960T3 (https=) |
| EA (1) | EA202193019A1 (https=) |
| ES (1) | ES2956471T3 (https=) |
| FI (1) | FI3982960T3 (https=) |
| GB (1) | GB201910116D0 (https=) |
| HR (1) | HRP20230696T1 (https=) |
| HU (1) | HUE063163T2 (https=) |
| IL (1) | IL288615A (https=) |
| LT (1) | LT3982960T (https=) |
| MA (1) | MA56187B1 (https=) |
| MD (1) | MD3982960T2 (https=) |
| MX (1) | MX2021014557A (https=) |
| MY (1) | MY205687A (https=) |
| PH (1) | PH12021552966A1 (https=) |
| PL (1) | PL3982960T3 (https=) |
| PT (1) | PT3982960T (https=) |
| RS (1) | RS64412B1 (https=) |
| SG (1) | SG11202113304YA (https=) |
| SI (1) | SI3982960T1 (https=) |
| SM (1) | SMT202300261T1 (https=) |
| TW (1) | TW202112370A (https=) |
| UA (1) | UA129869C2 (https=) |
| WO (1) | WO2020249977A1 (https=) |
| ZA (1) | ZA202110685B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| GB201910116D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| US20230381162A1 (en) * | 2020-10-23 | 2023-11-30 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
| JP2024505596A (ja) * | 2021-02-09 | 2024-02-06 | カルビスタ・ファーマシューティカルズ・リミテッド | 遺伝性血管性浮腫の治療 |
| US20250281397A1 (en) | 2022-04-27 | 2025-09-11 | Kalvista Pharmaceuticals Limited | Formulations of a plasma kallikrein inhibitor |
| CN116003386B (zh) * | 2022-11-20 | 2024-03-26 | 药康众拓(北京)医药科技有限公司 | 一种氘代n-苄基吡啶酮吡唑甲酰胺类化合物、药物组合物和用途 |
| WO2025172693A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
| WO2025172692A1 (en) | 2024-02-13 | 2025-08-21 | Kalvista Pharmaceuticals Limited | Oral sebetralstat for the treatment of an attack of hereditary angioedema |
| WO2026003532A1 (en) | 2024-06-28 | 2026-01-02 | Kalvista Pharmaceuticals Limited | Sebetralstat for the treatment of anxiety associated with hereditary angioedema |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| JP5322935B2 (ja) | 2006-07-31 | 2013-10-23 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬 |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| EP2590945B1 (en) | 2010-07-07 | 2014-04-30 | The Medicines Company (Leipzig) GmbH | Serine protease inhibitors |
| US20130210809A1 (en) | 2010-07-14 | 2013-08-15 | Christelle Boléa | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| MY174018A (en) | 2013-05-23 | 2020-03-04 | Kalvista Pharmaceuticals Ltd | Heterocyclic derivates |
| EP2815749A1 (en) * | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| EP2886107A1 (en) * | 2013-12-17 | 2015-06-24 | ObsEva S.A. | Oral formulations of pyrrolydine derivatives |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201721515D0 (en) * | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| GB201910116D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
-
2019
- 2019-07-15 GB GBGB1910116.1A patent/GB201910116D0/en not_active Ceased
-
2020
- 2020-06-15 EP EP23181261.1A patent/EP4282474A3/en active Pending
- 2020-06-15 SM SM20230261T patent/SMT202300261T1/it unknown
- 2020-06-15 KR KR1020217043374A patent/KR102748728B1/ko active Active
- 2020-06-15 BR BR112021024664A patent/BR112021024664A2/pt not_active Application Discontinuation
- 2020-06-15 FI FIEP20734283.3T patent/FI3982960T3/fi active
- 2020-06-15 PH PH1/2021/552966A patent/PH12021552966A1/en unknown
- 2020-06-15 TW TW109120108A patent/TW202112370A/zh unknown
- 2020-06-15 MX MX2021014557A patent/MX2021014557A/es unknown
- 2020-06-15 CN CN202080043365.6A patent/CN114126612A/zh active Pending
- 2020-06-15 EP EP20734283.3A patent/EP3982960B1/en active Active
- 2020-06-15 UA UAA202106869A patent/UA129869C2/uk unknown
- 2020-06-15 ES ES20734283T patent/ES2956471T3/es active Active
- 2020-06-15 HU HUE20734283A patent/HUE063163T2/hu unknown
- 2020-06-15 US US17/617,439 patent/US20220218680A1/en active Pending
- 2020-06-15 MA MA56187A patent/MA56187B1/fr unknown
- 2020-06-15 SG SG11202113304YA patent/SG11202113304YA/en unknown
- 2020-06-15 LT LTEPPCT/GB2020/051439T patent/LT3982960T/lt unknown
- 2020-06-15 MD MDE20220440T patent/MD3982960T2/ro unknown
- 2020-06-15 CA CA3142218A patent/CA3142218A1/en active Pending
- 2020-06-15 JP JP2021571931A patent/JP7356518B2/ja active Active
- 2020-06-15 WO PCT/GB2020/051439 patent/WO2020249977A1/en not_active Ceased
- 2020-06-15 SI SI202030247T patent/SI3982960T1/sl unknown
- 2020-06-15 DK DK20734283.3T patent/DK3982960T3/da active
- 2020-06-15 PT PT207342833T patent/PT3982960T/pt unknown
- 2020-06-15 EA EA202193019A patent/EA202193019A1/ru unknown
- 2020-06-15 RS RS20230620A patent/RS64412B1/sr unknown
- 2020-06-15 HR HRP20230696TT patent/HRP20230696T1/hr unknown
- 2020-06-15 MY MYPI2021007320A patent/MY205687A/en unknown
- 2020-06-15 PL PL20734283.3T patent/PL3982960T3/pl unknown
- 2020-06-15 AU AU2020293614A patent/AU2020293614B2/en active Active
- 2020-06-16 AR ARP200101681A patent/AR119158A1/es unknown
-
2021
- 2021-12-02 IL IL288615A patent/IL288615A/en unknown
- 2021-12-06 CL CL2021003244A patent/CL2021003244A1/es unknown
- 2021-12-20 ZA ZA2021/10685A patent/ZA202110685B/en unknown
-
2023
- 2023-03-06 CL CL2023000639A patent/CL2023000639A1/es unknown
- 2023-08-14 JP JP2023131860A patent/JP7688078B2/ja active Active
-
2025
- 2025-05-21 JP JP2025084646A patent/JP2025124716A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230696T1 (hr) | Liječenje hereditarnog angioedema | |
| RU2484815C2 (ru) | Продолжительное 24-часовое введение в кишечник леводопа/карбидопа | |
| CN101600438B (zh) | 疼痛疾病治疗剂 | |
| AU2008302190A1 (en) | Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors | |
| HK1252562A1 (zh) | 苯并咪唑衍生物用於夜间酸突破的用途 | |
| MX2012014334A (es) | Tratamiento de diabetes tipo 2. | |
| Ventafridda et al. | Non-steroidal antiinflammatory drugs as the first step in cancer pain therapy: double-blind, within-patient study comparing nine drugs | |
| RU2009119258A (ru) | Способ лечения воспалительных заболеваний кишечника | |
| JP2016507500A5 (https=) | ||
| JPWO2020249977A5 (https=) | ||
| US20120122919A1 (en) | Pharmaceutical composition combining tenatoprazole and a histamine h2-receptor antagonist | |
| TW202103709A (zh) | 用於治療患有慢性腎臟病之對象的方法 | |
| JPWO2020249979A5 (https=) | ||
| JP2003535897A (ja) | アンギオテンシンｉｉアンタゴニストの新規使用法 | |
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| NZ782935B2 (en) | Treatments of hereditary angioedema | |
| JP5809005B2 (ja) | Ｐｄｅ５阻害剤含有医薬組成物 | |
| CN101014333A (zh) | 包含洛索洛芬的口服组合物 | |
| RU2545687C1 (ru) | Способ эрадикации хеликобактер пилори гастродуоденальной зоны | |
| RU2611383C2 (ru) | Комбинированный препарат для устранения симптомов и лечения острых респираторных вирусных инфекций и гриппа | |
| JP4993998B2 (ja) | イブプロフェンを含有する医薬組成物 | |
| Tulachan et al. | Escitalopram induced priapism | |
| US7041706B2 (en) | Method for treating crohn's disease | |
| Uberti et al. | Gastric Acid-Related Damage | |
| TW200838534A (en) | Treatment for irritable bowel syndrome |